XML 70 R60.htm IDEA: XBRL DOCUMENT
v3.21.2

COLLABORATIONS AND OTHER ARRANGEMENTS (Details) - USD ($) shares in Millions |  |  |  | 3 Months Ended | 9 Months Ended
--- | --- | --- | --- | --- | ---
Mar. 13, 2021 | May 29, 2020 | May 27, 2020 | Sep. 30, 2021 | Mar. 31, 2021 | Sep. 30, 2020 | Sep. 30, 2021 | Sep. 30, 2020
Merck Sharp & Dohme Corp agreement |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |
Percent of global development and commercialization costs | 60.00% |  |  |  |  |  |  |
Revenue recognized |  |  |  | $ 0 |  |  | $ 0 |
Option period to license | 5 years |  |  |  |  |  |  |
Merck Sharp & Dohme Corp agreement | Merck |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |
Percent of global development and commercialization costs | 40.00% |  |  |  |  |  |  |
Merck Sharp & Dohme Corp agreement | Oral Formulation Product |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |
Net product sales threshold | $ 2,000,000,000 |  |  |  |  |  |  |
Percent of global product revenues | 65.00% |  |  |  |  |  |  |
Merck Sharp & Dohme Corp agreement | Injectable Formulation Product |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |
Net product sales threshold | $ 3,500,000,000 |  |  |  |  |  |  |
Percent of global product revenues | 65.00% |  |  |  |  |  |  |
Arcus stock purchase agreement | Arcus |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |
Ownership percentage by noncontrolling owners |  |  |  |  | 19.50% |  |  |
Other collaboration arrangements |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |
Cash payments made related to equity investments |  |  |  | 0 |  | $ 0 | 0 | $ 0
Upfront collaboration expenses related to other collaborative arrangements |  |  |  | $ 0 |  | $ 0 | $ 0 | $ 0
Arcus | Arcus stock purchase agreement |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |
Purchase period |  |  | 5 years |  |  |  |  |
Restriction period |  |  | 3 years |  |  |  |  |
Equity securities acquired (in shares) |  | 8.2 |  |  | 5.7 |  |  |
Payments to acquire equity securities |  | $ 261,000,000 |  |  | $ 220,000,000 |  |  |
Equity securities (in shares) |  |  |  | 13.8 |  |  | 13.8 |
Arcus | The “Stock Purchase Agreements” |  |  |  |  |  |  |  |
Collaborative Arrangements |  |  |  |  |  |  |  |
Maximum percentage of outstanding stock allowed to be purchased (up to) |  |  | 35.00% |  |  |  |  |

X
- Definition Cash Payments Made Related to Equity Investments + References No definition available. + Details
Name: | gild_CashPaymentsMadeRelatedToEquityInvestments
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Arrangement, License Oral Integrase Inhibitors, Option Period + References No definition available. + Details
Name: | gild_CollaborationArrangementLicenseOralIntegraseInhibitorsOptionPeriod
Namespace Prefix: | gild_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration Arrangement, Net Product Sales Threshold + References No definition available. + Details
Name: | gild_CollaborationArrangementNetProductSalesThreshold
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Arrangement, Percent Of Global Development And Commercialization Costs + References No definition available. + Details
Name: | gild_CollaborationArrangementPercentOfGlobalDevelopmentAndCommercializationCosts
Namespace Prefix: | gild_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaboration Arrangement, Percent Of Global Product Revenues + References No definition available. + Details
Name: | gild_CollaborationArrangementPercentOfGlobalProductRevenues
Namespace Prefix: | gild_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity Securities, FV-NI, Maximum Percentage Of Outstanding Stock Allowed To Be Purchased + References No definition available. + Details
Name: | gild_EquitySecuritiesFVNIMaximumPercentageOfOutstandingStockAllowedToBePurchased
Namespace Prefix: | gild_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity Securities, FV-NI, Purchase Period + References No definition available. + Details
Name: | gild_EquitySecuritiesFVNIPurchasePeriod
Namespace Prefix: | gild_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity Securities, FV-NI, Restriction Period + References No definition available. + Details
Name: | gild_EquitySecuritiesFVNIRestrictionPeriod
Namespace Prefix: | gild_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity Securities, FV-NI, Shares + References No definition available. + Details
Name: | gild_EquitySecuritiesFVNIShares
Namespace Prefix: | gild_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Equity Securities, FV-NI, Shares Acquired + References No definition available. + Details
Name: | gild_EquitySecuritiesFVNISharesAcquired
Namespace Prefix: | gild_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront Collaboration Expenses Related To Other Collaborative Arrangements + References No definition available. + Details
Name: | gild_UpfrontCollaborationExpensesRelatedToOtherCollaborativeArrangements
Namespace Prefix: | gild_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity. + References No definition available. + Details
Name: | us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 321 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 19 -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3444-108585 + Details
Name: | us-gaap_PaymentsToAcquireEquitySecuritiesFvNi
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_VariableInterestEntityLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_MerckSharpDohmeCorpLicenseAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=gild_MerckMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_OralFormulationProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=gild_InjectableFormulationProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_ArcusStockPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=gild_ArcusBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_OtherCollaborationArrangementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=gild_ArcusBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=gild_CommonStockPurchaseAgreementAndInvestorRightsAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |